Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.
Oral SERD Regimen May Prolong Efficacy in Second-Line Breast Cancer Care
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer
The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.
Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC
With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.
Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer
The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.
Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer
The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.
Adjuvant Alectinib Exhibits Sustained Survival Benefit in ALK+ NSCLC
Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.
Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma
A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.
Survival Improves With Perioperative Pembrolizumab in Early-Stage NSCLC
Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.
Zanzalintinib Combo Improves Survival in Pretreated Metastatic CRC
Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.
Temab-A Displays Early Efficacy in Locally Advanced/Metastatic PDAC
The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.
Dato-DXd May Be Next SOC in First-Line TNBC
Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.
Apalutamide/ADT Displays Long-Term Efficacy in Recurrent Prostate Cancer
Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.
PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer
Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.
Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC
Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.
Iza-Bren Increases Responses in Recurrent Nasopharyngeal Carcinoma
Data from the BL-B01D1-301 study support iza-bren as a potential standard of care for pretreated recurrent or metastatic nasopharyngeal carcinoma.
Sirexatamab Combo Shows Efficacy in DKK1-High Metastatic CRC Subgroups
Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.
Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial
Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.
Enfortumab Vedotin/Pembrolizumab Display Frontline Efficacy in PD-L1+ HNSCC
The investigator-evaluated ORR was 39.0% among those treated for recurrent/metastatic HNSCC, and the CR and PR rates were 9.8% and 29.3%, respectively.
Tislelizumab Regimen Exhibits Improved Survival in Locally Advanced ESCC
Patients with ESCC treated in 2 tislelizumab-based arms experienced higher composite complete response rates compared to chemoradiotherapy alone.
Tiragolumab Regimen Misses PFS End Point in Hepatocellular Carcinoma
Overall survival data in the IMbrave152/SKYSCRAPER-14 study are not anticipated to show statistical significance.
Durvalumab Quadruplet Displays Nonsuperior OS in Advanced Ovarian Cancer
In terms of OS among patients with non-tBRCA–mutated, HRD-positive disease, the median value was not reached in either durvalumab arm.
Durvalumab Combo Shows Consistent Outcomes in Advanced Pleural Mesothelioma
Slow accrual led to the early stopping of the phase 3 DREAM3R trial assessing durvalumab/chemotherapy in advanced pleural mesothelioma.
Enzalutamide Combo Shows No MFS Improvement in Advanced Prostate Cancer
Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
OptiTROP-Lung04 data show sacituzumab tirumotecan cut the risk of progression or death by 51% in patients with nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.
Exploring the Role of Gedatolisib in HR+/HER2-Negative Breast Cancer
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Disitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer
Disitamab vedotin plus toripalimab achieved a median 13.1-month PFS and median 31.5-month OS in patients with HER2-expressing advanced urothelial carcinoma.
Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer
At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.
Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer
Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer
A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.